Technology

& Pipeline

Technology

& Pipeline

The ImmTAC pipeline

Immunocore has a robust pipeline of wholly-owned and partnered ImmTAC programmes.

Alongside high value proprietary programmes, Immunocore has co-discovery and co-development programmes with Eli Lilly and discovery programmes, including milestones and royalties, with Genentech, GlaxoSmithKline and AstraZeneca (MedImmune).

 
 
Stage
 

Product

Indication
ImmTAC generation
IND
enabling

Phase I

Phase II

Phase III
Owner /
Collaborator
IMCgp100
Uveal melanoma

IMCgp100 checkpoint combination
Cutaneous melanoma

IMCgp100 SMI combination
Uveal melanoma

Internal programme
Lung / Head & Neck / Oesophageal
Lung / Ovarian / Breast / Endometrial

> 5 undisclosed internal programmes
Various

ImmTAC development programme
NSCLC / Bladder cancer / Synovial sarcoma

> 5 undisclosed partner programmes
Various